Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Forschungsstelle

INNOSUISSE

Projektnummer

62871.1 IP-LS

Projekttitel

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Projekttitel Englisch

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)
Kurzbeschreibung (Englisch)	Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids
Abstract (Deutsch)	Alentis Therapeutics AG is implementing unique anti-claudin 1 monoclonal antibodies as a novel approach for the treatment of liver fibrosis. This project aims at leveraging 3D-in vitro models to identify translational makers of target engagement.